Abstract
Platelet deposition, adhesion/aggregation, to the damaged vessel wall or atherosclerotic plaque components has shown to play a major role in hemostasis, thrombosis, and the development of atherosclerosis. Platelet-vessel wall interaction and thrombus formation is driven by blood flow rheology/hemodynamics (changes in local flow conditions), the nature of the flowing blood, and the characteristics of the triggering substrate (lesion type). An extracorporeal perfusion system (the Badimon chamber) was developed to investigate the dynamics of platelet deposition and thrombus formation on: (a) different surfaces (biological and synthetic); (b) under controlled blood flow conditions with varying degrees of stenosis mimicking various vascular conditions (patent and stenotic arteries); and (c) with varying perfusing blood treatments.
In the following chapter, we thoroughly describe this experimental approach that has helped to improve the understanding of the pathophysiology of the acute coronary syndromes (Badimon et al., Arteriosclerosis 6:312–320, 1986; Badimon et al., J Lab Clin Med 110:706–718, 1987; Badimon et al., Blood 73:961–967, 1989; Mailhac et al., Circulation 90:988–996, 1994) and is a useful tool for the study and screening of new antithrombotic and platelet-inhibitory compounds (Badimon et al., Thromb Haemost 71:511–516, 1994; Vilahur et al., Circulation 110:1686–1693; Vilahur et al., Thromb Haemost 92:191–200, 2004; Vilahur et al., Cardiovasc Res 61:806–816; Vilahur et al., Thromb Haemost 98:662–669, 2007; Vilahur et al., Thromb Haemost 97:650–657, 2007; Zafar et al., J Thromb Haemost 5:1195–1200, 2007; Lev et al., J Am Coll Cardiol 43:966–971) and for the evaluation of the thrombogenicity associated to synthetic/prosthetic surfaces (Badimon et al., J Biomater Appl 5:27–48, 1990; Badimon et al., ASAIO Trans 33:621–625, 1987) and/or plasma components (cholesterol, glucose levels, etc.) (Badimon et al., Arterioscler Thromb 11:395–402, 1991; Osende et al., J Am Coll Cardiol 38:1307–1312; 2001).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Badimon L, Vilahur G, Padro T. (2009) Lipoproteins, platelets and atherothrombosis. Rev Esp Cardiol. 62, 1161–1178.
Badimon L, Badimon JJ, Vilahur G, et al. (2002) Pathogenesis of the acute coronary syndromes and therapeutic implications. Pathophysiol Haemost Thromb. 32, 225–231.
Sakariassen KS, Aarts PA, de Groot PG, et al. (1983) A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med. 102, 522–535.
Baumgartner HR. (1973) The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res. 5, 167–179.
Martines E, McGhee K, Wilkinson C, et al. (2004) A parallel-plate flow chamber to study initial cell adhesion on a nanofeatured surface. IEEE Trans Nanobioscience. 3, 90–95.
Badimon L, Turitto V, Rosemark JA, et al. (1987) Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med. 110, 706–718.
Badimon L, Badimon JJ, Turitto VT, et al. (1990) Platelet interaction to prosthetic materials--role of von Willebrand factor in platelet interaction to PTFE. J Biomater Appl. 5, 27–48.
Badimon L, Badimon JJ, Turitto VT, et al. (1987) Role of von Willebrand factor in platelet interaction with an expanded PTFE surface. ASAIO Trans. 33, 621–625.
Badimon L, Badimon JJ. (1989) Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest. 84, 1134–1144.
Badimon L, Badimon JJ, Turitto VT, et al. (1987) Thrombosis: studies under flow conditions. Ann N Y Acad Sci. 516, 527–540.
Badimon L, Badimon JJ, Rand J, et al. (1987) Platelet deposition on von Willebrand factor-deficient vessels. Extracorporeal perfusion studies in swine with von Willebrand’s disease using native and heparinized blood. J Lab Clin Med. 110, 634–647.
Fuster V, Ip JH, Badimon L, et al. (1991) Importance of experimental models for the development of clinical trials on thromboatherosclerosis. Circulation. 83, IV15–25.
Badimon L, Badimon JJ, Galvez A, et al. (1986) Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis. 6, 312–320.
Mailhac A, Badimon JJ, Fallon JT, et al. (1994) Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation. 90, 988–996.
Toschi V, Gallo R, Lettino M, et al. (1997) Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 95, 594–599.
Badimon JJ, Lettino M, Toschi V, et al. (1999) Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 99, 1780–1787.
Vilahur G, Duran X, Juan-Babot O, et al. (2004) Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 92, 191–200.
Zafar MU, Vilahur G, Choi BG, et al. (2007) A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost. 5, 1195–1200.
Chelliah R, Lucking AJ, Tattersall L, et al. (2009) P-selectin antagonism reduces thrombus formation in humans. J Thromb Haemost. 7, 1915–1919.
Sarich TC, Osende JI, Eriksson UG, et al. (2003) Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost. 1, 999–1004.
Zafar MU, Vorchheimer DA, Gaztanaga J, et al. (2007) Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 98, 883–888.
Dangas G, Badimon JJ, Coller BS, et al. (1998) Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab. Arterioscler Thromb Vasc Biol. 18, 1342–1349.
Dewanjee MK, Rao SA, Didisheim P. (1981) Indium-111 tropolone, a new high-affinity platelet label: preparation and evaluation of labeling parameters. J Nucl Med. 22, 981–987.
Alfon J, Pueyo Palazon C, Royo T, et al. (1999) Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model. Thromb Haemost. 81, 822–827.
Badimon L, Fuster V, Chesebro JH, et al. (1983) New “ex vivo” radioisotopic method of quantitation of platelet deposition - studies in four animal species. Thromb Haemost. 50, 639–644.
Badimon L, Badimon JJ, Turitto VT, et al. (1989) Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate; the importance of perfusion conditions. Blood. 73, 961–967.
Badimon JJ, Weng D, Chesebro JH, et al. (1994) Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Thromb Haemost. 71, 511–516.
Vilahur G, Segales E, Salas E, et al. (2004) Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model. Circulation. 110, 1686–1693.
Vilahur G, Baldellou MI, Segales E, et al. (2004) Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects. Cardiovasc Res. 61, 806–816.
Vilahur G, Casani L, Badimon L. (2007) A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost. 98, 662–669.
Vilahur G, Pena E, Padro T, et al. (2007) Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Thromb Haemost. 97, 650–657.
Lev EI, Hasdai D, Scapa E, et al. (2004) Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation. J Am Coll Cardiol. 43, 966–971.
Badimon JJ, Badimon L, Turitto VT, et al. (1991) Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb. 11, 395–402.
Osende JI, Badimon JJ, Fuster V, et al. (2001) Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol. 38, 1307–1312.
Acknowledgments
This article has been possible thanks to support from PNS 2006–10091 (to L.B.) from the Spanish Ministry of Science; Lilly Foundation (to L.B.) and CIBEROBN06 (to L.B.). We thank Fundacion Juan Serra, Barcelona, for their continuous support. G.V. is recipient of a grant from the Spanish Ministry of Science and Innovation (RyC, MICINN).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Badimon, L., Padro, T., Vilahur, G. (2012). Extracorporeal Assays of Thrombosis. In: Gibbins, J., Mahaut-Smith, M. (eds) Platelets and Megakaryocytes. Methods in Molecular Biology, vol 788. Springer, New York, NY. https://doi.org/10.1007/978-1-61779-307-3_4
Download citation
DOI: https://doi.org/10.1007/978-1-61779-307-3_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-61779-306-6
Online ISBN: 978-1-61779-307-3
eBook Packages: Springer Protocols